Olaparib (Lynparza) was the first drug to be approved in 2014 by EMA and FDA in clinical use as monotherapy for the treatment of advanced germline BRCA1/2m ovarian cancer (Wiggans et al., 2015) (Deeks, 2015). Here, BRCA1 is linked to ovarian cancer.